scholarly journals A comparison of clofarabine with ara-C, each in combination with daunorubicin as induction treatment in older patients with acute myeloid leukaemia

Leukemia ◽  
2016 ◽  
Vol 31 (2) ◽  
pp. 310-317 ◽  
Author(s):  
A K Burnett ◽  
◽  
N H Russell ◽  
R K Hills ◽  
J Kell ◽  
...  
Keyword(s):  
Acute Myeloid Leukaemia ◽  
Myeloid Leukaemia ◽  
Older Patients ◽  
Induction Treatment ◽  
Acute Myeloid

Efficacy and feasibility of intensive induction therapy in very elderly patients with acute myeloid leukaemia

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 16528-16528
Author(s):  
G. Biaggi ◽  
A. Santagostino ◽  
D. Manachino ◽  
T. Posca ◽  
G. Forti ◽  
...  
Keyword(s):  
Elderly Patients ◽  
Acute Myeloid Leukaemia ◽  
Myeloid Leukaemia ◽  
Performance Status ◽  
Best Supportive Care ◽  
Induction Treatment ◽  
Very Elderly ◽  
Ecog Performance Status ◽  
Leukaemia Therapy ◽  
Acute Myeloid

16528 Background: Intensive Induction Treatment (IIT) increases chances of longer survival in acute myeloid leukaemia (AML). Our aim was to improve outcome and to evaluate safety and tolerability of IIT in very elderly patients (pts). Otherwise they have a median surviving time of 11 weeks without treatment. Methods: From October 2003 to November 2005 we treated 23 pts, 16 Males (M) and 7 Female (F); median age 75.5 years (range 68–95). According FAB classification they were 1 M0, 10 M1, 5 M2, 6 M4, 1 M5. ECOG performance status (PS) was 0 in 6 pts, 1 in 5 pts, 2 in 7 pts and 3 in 5 pts. All pts underwent IIT with different schedules: only a female 95 years old had less intensive treatment. Immune-chemotherapy was also admitted. Schedules were: 3+7 IDA+ARA-C in 8 pts; MY-FLAI in 7 pts; VP+ARA-C 1 = ≥ 5 in 2 pts; IDA+ARA-C 1 = ≥ 2 in 4 pts; ARA-C + 6TG in 1 pt. Eleven pts underwent second line treatment. Results: Five pts are alive and 18 dead. We obtained 7 complete responses (CR) (32%) and 1 partial response (PR) (RR 36%);. The median CR duration was 7.5 months (range 1–12).Throughout IIT we observed 5 toxic deaths (23%) because of infections and 2 deaths not leukaemia therapy related (heart failure). The median Overall Survival (OS) was 9 months. Conclusions: Despite the toxic deaths due to the treatment, we obtained in 32% of the pts CR longer compared to palliative or best supportive care; also the median OS was longer than we can expected without chemotherapy. Our data support in our opinion the feasibility and the utility of an IIT in very elderly patients with good PS. No significant financial relationships to disclose.

Allo-HCT regimens with low toxicity needed in older patients with acute myeloid leukaemia

2016 ◽  
Vol 17 (1) ◽  
pp. e1
Author(s):  
Mohamed A Kharfan-Dabaja ◽  
Taiga Nishihori ◽  
Ali Bazarbachi
Keyword(s):  
Acute Myeloid Leukaemia ◽  
Myeloid Leukaemia ◽  
Older Patients ◽  
Low Toxicity ◽  
Acute Myeloid

Outcomes of non‐myeloablative allogeneic stem cell transplant in older patients with acute myeloid leukaemia in first remission

2021 ◽  
Vol 51 (11) ◽  
pp. 1954-1958
Author(s):  
Phillip C. Nguyen ◽  
Kate Manos ◽  
Chun Y. Fong ◽  
Anthony P. Schwarer ◽  
Ing S. Tiong ◽  
...  
Keyword(s):  
Stem Cell ◽  
Acute Myeloid Leukaemia ◽  
Myeloid Leukaemia ◽  
Older Patients ◽  
Stem Cell Transplant ◽  
Cell Transplant ◽  
Allogeneic Stem Cell Transplant ◽  
First Remission ◽  
Acute Myeloid
Sign in / Sign up

Export Citation Format

Share Document